

ASX RELEASE

13 February 2025

Notice Pursuant to ASX Listing Rule 3.11.2 – Change of Exercise Price of Options

Amplia Therapeutics Limited (ASX: ATX) (“Amplia” or the “Company”) wishes to advise that following completion, in December 2024, of the A\$13m Capital Raising announced 30 October 2024 the following changes to the exercise prices of its unlisted options have been affected in accordance with ASX Listing Rule 6.22.2:

| Details of Options | New Exercise Price |
|--|--------------------|
| Options Exercise Price \$0.15 Expiry Date 2 September 2025 | \$0.1433 |
| Options Exercise Price \$0.20 Expiry Date 2 September 2025 | \$0.1933 |
| Options Exercise Price \$0.26 Expiry Date 6 September 2025 | \$0.2533 |
| Options Exercise Price \$0.26 Expiry Date 7 October 2025 | \$0.2533 |
| Options Exercise Price \$0.135 Expiry Date 5 June 2028 | \$0.1320 |

In accordance with ASX Listing Rule 3.11.2 these changes are to become effective on 20 February 2025.

Replacement holding statements and application forms for exercising options will be despatched to all option holders.

This ASX announcement is authorised for release by the Board.

- End -

Investor Contact:

Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com

Media Contact:

HACK Director, Haley Chartres
haley@hck.digital
+61 423 139 163

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on [Twitter](https://twitter.com/ampliatx) (@ampliatx) and [LinkedIn](https://www.linkedin.com/company/ampliatx).

For personal use only